Allogene Therapeutics (ALLO) Debt/EBITDA US GAAP (year values)
2021 2022 2023 2024 2025   LTM ? CAGR 5 years ?
Debt/EBITDA 2.26 1.30 1.13 0.83 0.90   1.11  
Changes by years, y/y, % -42% -43% -13% -27% +9%     -25.4%
Compare with other companies

Allogene Therapeutics. Debt/EBITDA

Allogene Therapeutics. Debt/EBITDA, changes, %

Allogene Therapeutics (ALLO) Debt/EBITDA US GAAP (quarter values)
2025Q1 2025Q2 2025Q3 2025Q4 2026Q1   LTM ?
Debt/EBITDA 0.83 0.87 0.84 0.92 1.11   1.11
Changes by years, y/y, % -23% -38% +4% +11% +33%    
Changes by quarters, q/q, % +1% +4% -3% +9% +20%    

Allogene Therapeutics. Debt/EBITDA

Allogene Therapeutics. Debt/EBITDA, changes, y/y, %

Allogene Therapeutics. Debt/EBITDA, changes, q/q, %


Have an idea?
Blogs All blogs wire
Most useful
Most commented
NEWS
Trade Signals
Answers to questions
Books reviews
Corporate blogs
Forums All forums wire
Common
Stocks
Algotrading
Options
Cryptocurrencies
Forex
Brokers rating
Stocks Heat Map
Quotes
Fundamental analysis
Financials
Dividends
My portfolio
All companies
Stocks Calendar
Smartlab Smartlab Values
SiteMap
Ads
Contacts

Rules
Help
Feedback
Moscow Exchange is the source and the owner of marketdata. The users haven't right of further distribution or presentation of any data without written permission of Moscow Exchange, haven't right to create modified information for further public distribution to third parties.